Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

A Life Sciences Project Accelerator Kicks into High Gear

XPhyto Therapeutics Corp. ( CSE: XPHY ) (FSE: 4XT) (OTC: XPHYF) has been a hot story lately, especially in Germany, due to its recent commercialization of a super-fast PCR test kit for definitively diagnosing COVID-19 infections in point-of-care settings. The company rec...
Marc Davis | May 10, 2021 |

XPhyto: Proof of Concept for Mescalin Synthesis

It’s become a much talked-about story on both sides of the Atlantic. XPhyto Therapeutics Corp. ( CSE: XPHY ) (FSE: 4XT) (OTCQB: XPHYF) has earned considerable media coverage in recent months due to its expansion into the development of psychedelic d...
Marc Davis | June 9, 2021 |

Meet the Company Diving into the Cannabis 3.0 Market

The first and second waves of the cannabis market have come and gone, which has only prepared us for the cannabis 3.0 market and all the derivative products that come with it. Companies like Ayurcann Holdings Corp. ( CSE:AYUR , OTCQB:AYURF , Forum ) are...
Jocelyn Aspa | March 23, 2022 |

Apogee Enterprises Shares Trade Up 12.5% on Q2 Earnings and Yearly Outlook

Shares of Apogee Enterprises are trading higher today after the commercial and architectural glass and framing company announced Q2/20 earnings and updated its estimates for the rest of the year. This morning commercial and architectural glass fabricator and window fr...
Streetwise Reports | September 18, 2019 |

Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial

Axsome Therapeutics shares traded 14% higher today after the company reported that its narcolepsy drug candidate AXS-12 achieved its primary endpoint in the Phase 2 CONCERT Study. This morning before U.S. markets opened, clinical-stage biopharmaceutical company Axsom...
Streetwise Reports | December 4, 2019 |

Biopharma to Test Immunity Activator in Advanced Solid Cancers

The company's plans for and approach to one of its most advanced drug candidates are discussed in an H.C. Wainwright & Co. report. In a Dec. 12 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that BioXcel Therapeutics Inc. (BTAI:NASDAQ) plans to ...
Streetwise Reports | December 19, 2019 |

Paratek Pharma Awarded $285 Million BARDA Contract to Combat Anthrax

Shares of Paratek Pharmaceuticals traded 40% higher today after the firm announced it was awarded a BARDA BioShield program contract valued at up to $285 million for NUZYRA used to treat anthrax. Late yesterday afternoon, biopharmaceutical company Paratek Pharmaceuti...
Streetwise Reports | December 20, 2019 |

U.S.-Based Biotech 'Growing into a Giant with AI'

How Moderna uses and benefits from digitization and artificial intelligence are described in a ROTH Capital Partners report. In a March 5 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that a site visit to Moderna Inc.'s (MRNA:NASDAQ) ...
Streetwise Reports | March 9, 2020 |

Novavax Shares Rise 9% Upon Initiating Phase 1/2 COVID-19 Vaccine Clinical Trial

Novavax shares traded higher after the company reported it enrolled the first participants in its Phase 1 clinical study of NVX CoV2373. Novavax Inc. (NVAX:NASDAQ) , which focuses its efforts on developing next-generation vaccines to address infectious diseases, ye...
Streetwise Reports | May 27, 2020 |

Buzz on the Bullboards: Summer's most talked about stocks

August has been a rough month for North American stock markets, with red days and a lot of flat trading activity. Shares of U.S. banks fell this week after several regional lenders were hit with a credit downgrade. Retailers are stuck with products that aren&CloseCurl...
Jonathon Brown | August 24, 2023 |
1 2 3 4 5 6 7 8 9 10 ...